Lpath, Inc.

Mor Research Applications Ltd.

Curetech Ltd.

Chugai Seiyaku Kabushiki Kaisha

Imclone Systems, Inc.

Chugai Seiyaku Kabushiki

Steven Tarran Jones

William A Garland

Roger A Sabbadini

Genevieve Hansen

David Gareth Williams

Jose William Saldanha

Masayuki Tsuchiya

Koh Sato

Mary M Bendig

Britta Hardy

Leah Klapper

Neil I Goldstein

Nicholas A Giorgio

Compositions and methods for making and using humanized anti-LPA monoclonal antibodies, and fragments and derivatives thereof, are described.

Humanized antibody compositions and methods for binding lysophosphatidic acid

The present invention relates to anti-S1P agents, particularly humanized monoclonal antibodies (and antigen binding fragments thereof) specifically reactive with S1P, compositions containing such antibodies (or fragments), and the use of such antibodies (or fragments), for example, to treat diseases and conditions associated with aberrant levels of S1P.

Humanized antibodies and compositions for binding sphingosine-1-phosphate

The present invention relates to anti-S1P agents, for example, humanized monoclonal antibodies, and their uses for detection of S1P or for treatment of diseases and conditions associated with S1P.

Compositions and methods for binding sphingosine-1-phosphate

Methods of using humanized antibodies and compositions for binding sphingosine-1-phosphate

The present invention provides to a humanized monoclonal antibody having immunostimulatory effects. This antibody binds specifically to B lymphoblastoid cells, induces proliferation and activation of peripheral blood lymphocytes, particularly T cells, and is capable of eliciting an anti-tumor effect upon administration to subjects suffering from an immune deficiency.

Humanized immunomodulatory monoclonal antibodies for the treatment of immunodeficiency

Nucleic acids coding for humanized antibodies for binding sphingosine-1-phosphate

The present invention provides to a humanized monoclonal antibody having immunostimulatory effects. This antibody binds specifically to B lymphoblastoid cells, induces proliferation and activation of peripheral blood lymphocytes, particularly T cells, and is capable of eliciting an anti-tumor effect upon administration to subjects suffering from cancer.

Human immunomodulatory monoclonal antibodies for the treatment of cancer

A reshaped human antibody to the human IL-6R, comprising: Since major portion of the reshaped human antibody is derived from a human antibody and the mouse CDRs which are less immunogenic, the present reshaped human antibody is less immunogenic to human, and therefor is promised for therapeutic uses.

Reshaped human antibody to human interleukin-6 receptor

The present invention provides to a humanized monoclonal antibody having immunostimulatory effects. This antibody binds specifically to B lymphoblastoid cells, induces proliferation and activation of peripheral blood lymphocytes, and is capable of eliciting an anti-tumor effect upon administration to subjects suffering from cancer.

Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency

A nucleic acid is provided which encodes a humanized antibody or fragment thereof, which encodes a protein which binds to human EGF-receptor. Monoclonal antibody 225 is the complementary determining region (CDR) donor.

Humanized anti-EGF receptor monoclonal antibody

A reshaped human antibody to the human IL-6R, comprising:

Growing community of inventors

Radlett, United Kingdom

Steven Tarran Jones